Wall Street " BREAN CAPITAL RAISES KERX TO ** $15 ** TARGET" LINKED.
By Leah Powell | More Articles
January 29, 2013
Page 1 of 5
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX): Current Price: $8.10
The company’s price target has been increased to $15 by Brean Capital due to positive Ph III Zerenex data. The stock has a Buy rating.